Literature DB >> 19224812

The utility of ketamine for the preoperative management of a patient with Parkinson's disease.

Justin J Wright1, Peter D Goodnight, Matthew D McEvoy.   

Abstract

Loss of dopaminergic neurons from the substantia nigra characterizes the classical pathology of Parkinson's disease, but persistent activation of N-methyl-D-aspartate receptors is also a major component. During difficult airway management in a patient with advanced Parkinson's disease, the use of low-dose (20 mg) i.v. ketamine resulted in complete abolition of severe tremor and dysarthria. This led to the current case report in which low-dose ketamine was used for preoperative sedation and dyskinesia attenuation. Prior research and our experience would suggest that low-dose ketamine, titrated to effect, may provide optimal patient comfort and perioperative control of Parkinsonian tremor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224812     DOI: 10.1213/ane.0b013e3181924025

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  8 in total

Review 1.  [Parkinson's disease. Perioperative management and anesthesia].

Authors:  U Wüllner; J Standop; O Kaut; V Coenen; A Kalenka; F Wappler
Journal:  Anaesthesist       Date:  2012-02       Impact factor: 1.041

2.  Treatment paradigms in Parkinson's Disease and Covid-19.

Authors:  Iro Boura; Lucia Batzu; Espen Dietrichs; Kallol Ray Chaudhuri
Journal:  Int Rev Neurobiol       Date:  2022-05-28       Impact factor: 4.280

3.  Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings).

Authors:  Georges Mion; Thierry Villevieille
Journal:  CNS Neurosci Ther       Date:  2013-04-10       Impact factor: 5.243

4.  Parkinson's disease and anaesthesia.

Authors:  Safiya I Shaikh; Himanshu Verma
Journal:  Indian J Anaesth       Date:  2011-05

5.  Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia.

Authors:  Mitchell J Bartlett; Andrew J Flores; Tony Ye; Saskia I Smidt; Hannah K Dollish; Jennifer A Stancati; Drew C Farrell; Kate L Parent; Kristian P Doyle; David G Besselsen; Michael L Heien; Stephen L Cowen; Kathy Steece-Collier; Scott J Sherman; Torsten Falk
Journal:  Exp Neurol       Date:  2020-07-25       Impact factor: 5.330

6.  Case Reports Showing a Long-Term Effect of Subanesthetic Ketamine Infusion in Reducing l-DOPA-Induced Dyskinesias.

Authors:  Scott J Sherman; Miguel Estevez; Ari B Magill; Torsten Falk
Journal:  Case Rep Neurol       Date:  2016-02-26

Review 7.  NMDA antagonists for treating the non-motor symptoms in Parkinson's disease.

Authors:  Brigitte Vanle; William Olcott; Jaime Jimenez; Luma Bashmi; Itai Danovitch; Waguih William IsHak
Journal:  Transl Psychiatry       Date:  2018-06-15       Impact factor: 6.222

8.  Preoperative Evaluation of Parkinson's Disease.

Authors:  Bianca C Woodruff; David Garcia; Shobhana Chaudhari
Journal:  Cureus       Date:  2021-06-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.